Psoriasis and Psoriatic Disorders Clinical Trials

A listing of Psoriasis and Psoriatic Disorders medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

 

Arizona

Arizona Arthritis & Rheumatology Research, PLLC
Glendale Arizona 85304

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Arizona Research Center
Phoenix Arizona 85023

A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214(Study Medication) Versus Enbrel in Subjects With Chronic Plaque Psoriasis.

California

University of California, Irvine Dermatology Clinical Research Center
Irvine California

A Multi-Center, Open Label, Phase 1 Study to Evaluate the Safety of Both A Prospective, Observational Study to Estimate the Proportion of Subjects with Plaque Psoriasis who Achieve Complete Clearance on Biologics

University of California, Irvine Dermatology Clinical Research Center
Irvine California 92697

Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

Dermatology Research Associates
Los Angeles California 90045

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Dermatology Specialists, Inc.
Oceanside California 92056

A national, multi-center, randomized, double-blind, 4 arm, 8 week study in subjects with psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs)

Dermatology Specialists, Inc.
Oceanside California 92056

A Phase 3, Multi-site, randomized, mixed-blind, parallel-group treatment withdrawl and re-treatment study of the efficacy and safety of 2 oral doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Dermatology Specialists, Inc.
Oceanside California 92056

You may be interested in learning about a clinical research study of an investigational study medication for symptoms associated with plaque psoriasis

Stanford University School of Medicine
Palo Alto California 94304

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Connecticut

New England Research Associates, LLC
Trumbull Connecticut 06611

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Florida

Rheumatology Associates of Central Florida, PA
Orlando Florida 32806

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Millennium Research
Ormond Beach Florida 32174

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Arthritis Center, Inc.
Palm Harbor Florida 34684

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

University of South Florida - Morsani Center for Advance Healthcare
Tampa Florida 33612

A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 17 years of age) with mild to moderate plaque psoriasis

University of South Florida - Morsani Center for Advance Healthcare
Tampa Florida 33612

A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects With Chronic Plaque Psoriasis

University of South Florida - Morsani Center for Advance Healthcare
Tampa Florida 33612

Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis

Georgia

Columbus Regional Research Institute
Columbus Georgia 31904

Considering potential research options for managing psoriasis?

Illinois

Northwestern University
Chicago Illinois 60611

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Maryland

The Center For Rheumatology And Bone Research
Wheaton Maryland 20902

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Massachusetts

Tufts Medical Center
Boston Massachusetts 02111

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Brigham & Women's Hospital
Boston Massachusetts 02115

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Clinical Pharmacology Study Group
Worcester Massachusetts 01605

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Michigan

University of Michigan
Ann Arbor Michigan 48109

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

Minnesota

St. Paul Rheumatology, PA
Eagan Minnesota 55121

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Missouri

Clayton Medical Research
St. Louis Missouri 63117

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Nebraska

Physician Research Collaboration, LLC
Lincoln Nebraska 68516

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Nevada

New Jersey

New York

Sadick Research Group
New York New York 10075

A multi-center, double bind, randomized, placebo-controlled parallel-group study for moderate to severe scalp psoriasis

The Rockefeller University Hospital
New York New York 10065

Comparative analysis of small and large plaque psoriasis

Rockefeller University
New York New York 10065

Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig)for the Treatment of Psoriasis Vulgaris (PAUSE)

North Carolina

PMG Research of Cary
Cary North Carolina 27518

Plaque Psoriasis – Moderate to Severe

Ohio

Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati Ohio 45219

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Paramount Medical Research & Consulting, LLC
Middleburg Heights Ohio 44130

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Pennsylvania

East Penn Rheumatology Associates, P.C.
Bethlehem Pennsylvania 18015

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Altoona Center for Clinical Research
Duncansville Pennsylvania 16635

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Rhode Island

Clinical Partners, LLC
Johnston Rhode Island 02919

Opportunity to participate: New Psoriasis Study Being Conducted

Tennessee

West Tennessee Research Institute
Jackson Tennessee 38305

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Texas

Metroplex Clinical Research Center
Dallas Texas 75231

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Research Across America
Dallas Texas

Pediatric Psoriasis Research Study

Pioneer Research Solutions, Inc.
Houston Texas 77008

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Research Across America, Plano
Plano Texas 75093

Plaque Psoriasis Research Study